Lonza Pharma & Biotech and Innosieve Diagnostics announced today an exclusive distribution agreement for rapid bioburden testing technology. This agreement expands Lonza’s extensive offering of ...
Another driver contributing to the market growth is the growing emphasis on regulatory compliance. Regulatory authorities across the globe are imposing strict guidelines and regulations regarding ...
The quality of water for pharmaceutical production (purified water, water for injection, and ultrapure water) is quantified and regulated through four parameters – total organic carbon (TOC), ...
When sterilizing medical devices, sterilization personnel rely on bioburden counts as part of determining and maintaining the sterilization process. In the following Q&A, Martell Winters, senior ...
Researchers and therapeutic manufacturers have long relied on classical microbiological methods to check their samples and surfaces for microbial contamination, primarily using lengthy ...
As biopharma companies fine-tune their strategies for continuous bioprocessing, bioburden control has become a top priority. The approaches that worked for batch processing are inadequate for ...
WILMINGTON, Mass.—October 20, 2014 – Charles River Laboratories International, Inc. (NYSE: CRL) today introduced the PTS-Micro™ system, a new technology platform designed for rapid microbial burden ...
Bioburden testing market projected to grow from $1.40B in 2024 to $3.30B by 2032, fueled by heightened food safety and healthcare demands. US, NY, UNITED STATES, March 18, 2025 /EINPresswire / -- In ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results